CLDN18 and neoplasm: Across SPOTLIGHT and GLOW, the combined prevalence of CLDN18.2 positivity, defined as ≥ 75% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining using the VENTANA CLDN18 (43-14A) RxDx Assay (for Investigational Use Only; VMSI/Roche), was 38.4% (1730/4507) among all screened patients with valid CLDN18 IHC results (Table 1 and Fig. 2).